Davis Polk advised BiondVax Pharmaceuticals Ltd. in the offering.
BiondVax Pharmaceuticals Ltd. closed its registered at-the-market offering of shares of its American depositary shares for up to a maximum offering price of $100 million.
Headquartered in Jerusalem, Israel, BiondVax is a clinical stage biopharmaceutical company focused on developing and, ultimately, if approved, commercializing immunomodulation therapies for infectious diseases. The company believes its vaccine candidate M-001 has the potential to become an attractive alternative to existing influenza vaccines.
The Davis Polk capital markets team advising BiondVax included partners Michael Kaplan (Picture) and Yasin Keshvargar and associates Gil Savir, Chris Van Buren and Genevieve A. Lewis. Counsel Alon Gurfinkel and associate Omer Harel provided tax advice.
Involved fees earner: Alon Gurfinkel – Davis Polk & Wardwell; Omer Harel – Davis Polk & Wardwell; Michael Kaplan – Davis Polk & Wardwell; Yasin Keshvargar – Davis Polk & Wardwell; Gil Savir – Davis Polk & Wardwell; Chris Van Buren – Davis Polk & Wardwell;
Law Firms: Davis Polk & Wardwell;
Clients: BiondVax Pharmaceuticals Ltd.;